Retatrutide Delivers 28.3% Weight Loss in Lilly's TRIUMPH-1 Phase 3 Trial
CONFIRMED87% CONFIDENCELilly's release is datelined "INDIANAPOLIS, May 21, 2026" and says the company "today announced positive topline results from TRIUMPH-1".[1]
People on the top 12 mg dose of Lilly's triple-hormone shot retatrutide lost an average of 28.3% of their body weight (70.3 lbs) over 80 weeks, and 30.3% by two years in the extension - weight loss at the level of bariatric surgery.
1.00